Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 1.00 |
| ▸ | HCK | P08631 | 4/20 | 0.72 |
| ▸ | SRC | P12931 | 4/20 | 0.72 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763358 | 1.00 | BRAF (1.00) | BRAFHCKSRCMAPK12MAPK14 | |
| SCHEMBL28698521 | 0.95 | BRAF (0.91) | BRAFHCKSRCMAPK12MAPK14 | |
| SCHEMBL28685990 | 0.94 | BRAF (0.89) | BRAFHCKSRCMAPK12MAPK14 | |
| SCHEMBL31046800 | 0.94 | BRAF (1.00) | BRAFHCKSRCMAPK12MAPK14 | |
| SCHEMBL3173602 | 0.94 | BRAF (1.00) | BRAFHCKSRCMAPK12MAPK14 | |
| SCHEMBL29437796 | 0.94 | BRAF (1.00) | BRAFHCKSRCMAPK12MAPK14 | |
| SCHEMBL28700803 | 0.94 | BRAF (0.88) | BRAFHCKSRCMAPK12MAPK14 | |
| SCHEMBL28707062 | 0.94 | BRAF (0.88) | BRAFHCKSRCMAPK12MAPK14 | |
| SCHEMBL29396296 | 0.94 | BRAF (0.88) | BRAFHCKSRCMAPK12MAPK14 | |
| SCHEMBL28698538 | 0.93 | BRAF (0.86) | BRAFHCKSRCMAPK12MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102277-A1 | COMBINATION THERAPIES COMPRISING IKZF2 DEGRADER COMPOUNDS | Plexium, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| EP-4676540-A1 | PANRAS INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | Novartis AG (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| US-20250353847-A1 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| WO-2025215536-A1 | MACROCYCLIC PANRAS INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2025-10-16 | — | — | WO | disclosed |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-18 | — | — | US | disclosed |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230056470-A1 | USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230037639-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
| WO-2022243846-A1 | COMBINATION THERAPIES | NOVARTIS AG (CH) | 2022-11-24 | — | — | WO | disclosed |
| EP-4076660-A1 | USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022215011-A1 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2022-10-13 | — | — | WO | disclosed |
| CN-115052662-A | Use of anti-TGF-beta antibodies and checkpoint inhibitors for treating proliferative diseases | 诺华股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022115477-A1 | BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056470-A1 | USES OF ANTI-TGF-BETA ANTIBODIES AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | TGFBR1, TGFB1, TGFBR2 | BRAF 196/4885HCK 2660/4885SRC 1218/4885 |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, RXFP3, NPY2R | BRAF 2624/4885HCK 2962/4885SRC 3114/4885 |
| US-20250353847-A1 | CRYSTALLINE FORMS OF AN AKRIC3 DEPENDENT KARS INHIBITOR | AKR1C3, AKR1C1, AKR1C2 | BRAF 1755/4885HCK 4145/4885SRC 4225/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | BRAF 2075/4885HCK 483/4885SRC 995/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | BRAF 879/4885HCK 487/4885SRC 60/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | BRAF 2246/4885HCK 3265/4885SRC 1348/4885 |
| US-20250339547-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | MET, BCL3, BCL9 | BRAF 408/4885HCK 1741/4885SRC 67/4885 |
| US-20220144798-A1 | SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, RXFP3, NPY2R | BRAF 2624/4885HCK 2962/4885SRC 3114/4885 |
| US-20230037639-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NPY2R, NPY5R, RXFP1 | BRAF 717/4885HCK 2547/4885SRC 1817/4885 |
| US-20220144807-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | RXFP3, AVPR2, RXFP1 | BRAF 2830/4885HCK 2783/4885SRC 3072/4885 |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | AVPR2, RXFP3, OPRD1 | BRAF 2803/4885HCK 3005/4885SRC 2779/4885 |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, HTR1D, RXFP1 | BRAF 3718/4885HCK 1378/4885SRC 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.